All In Biotech

Drug Trial Radar · NCT05624112

Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China

Open-label Exploratory Study to Evaluate the Effect of Dupilumab on Skin Barrier Function in Chinese Patients With Moderate to Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

44

Actual

Start

Nov 25, 2022

Primary completion

Jan 25, 2024

Study completion Jan 25, 2024

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Nov 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a 16-week, open label, exploratory study designed to investigate dupilumab's effect on skin barrier function as measured by transepidermal water loss (TEWL) before and after skin tape stripping. During the first 2 treatment weeks, patients will have 2 on-site visits/week, followed by one on-site visit/week up to Week 4, one on-site visit every two weeks from Week 4 to Week 8, and one on-site visit every 4 weeks up to Week 16 End of Treatment phase visit (EoT) thereafter. A follow-up visit by phone 4 weeks after the last study assessment at Week 16 will end the study for each participant (End of Study: EoS). The maximum duration of the study per participant will be 24 weeks.

Conditions

  • Atopic Dermatitis
  • Dermatitis Atopic

Interventions

  • DupilumabDrug

    Dupilumab solution in a pre-filled syringe for Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline in TEWL after 5 skin tape stripping (STS) assessed on lesional skin at Week16 in AD patients.Time frame: From baseline to week16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital)

    Guangzhou, Guangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.